Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) to a hold rating in a research report released on Saturday.

Several other analysts have also recently weighed in on ELOX. Lifesci Capital assumed coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price target on the stock. Guggenheim assumed coverage on shares of Eloxx Pharmaceuticals in a research report on Monday, July 20th. They issued a “buy” rating and a $43.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $41.50.

Eloxx Pharmaceuticals Stock Performance

Eloxx Pharmaceuticals stock opened at $18.45 on Friday. Eloxx Pharmaceuticals has a 52 week low of $15.67 and a 52 week high of $19.36. The business’s 50-day simple moving average is $16.66. The stock has a market capitalization of $12.73 million, a PE ratio of -1.21 and a beta of -1,863.11.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.